Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Drug-drug interactions in pharmaceutical development [[electronic resource] /] / edited by Albert P. Li
| Drug-drug interactions in pharmaceutical development [[electronic resource] /] / edited by Albert P. Li |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley-interscience, c2008 |
| Descrizione fisica | 1 online resource (261 p.) |
| Disciplina |
615.7045
615/.7045 |
| Altri autori (Persone) | LiA. P |
| Collana | Wiley series in drug discovery and development |
| Soggetto topico |
Drug interactions
Drug development |
| ISBN |
1-282-02206-7
9786612022067 0-470-18792-1 0-470-18791-3 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
DRUG-DRUG INTERACTIONS IN PHARMACEUTICAL DEVELOPMENT; CONTENTS; Preface; Contributors; 1 In Vitro Evaluation of Metabolic Drug-Drug Interactions: Concepts and Practice; 1.1 Introduction; 1.2 Mechanisms of Adverse Drug-Drug Interactions; 1.2.1 Pharmacological Interactions; 1.2.2 Pharmacokinetic Interactions; 1.3 Drug Metabolism; 1.3.1 Phase I Oxidation; 1.3.2 Phase II Conjugation; 1.4 CYP Isoforms; 1.5 Human In Vitro Experimental Systems for Drug Metabolism; 1.5.1 Hepatocytes; 1.5.2 Liver Postmitochondrial Supernatant (PMS); 1.5.3 Human Liver Microsomes; 1.5.4 Recombinant P450 Isoforms (rCYP)
1.5.5 Cytosol1.6 Mechanisms of Metabolic Drug-Drug Interactions; 1.7 Mechanism-Based Approach for Evaluation of Drug-Drug Interaction Potential; 1.7.1 Metabolic Phenotyping; 1.7.2 Evaluation of Inhibitory Potential for Drug-Metabolizing Enzymes; 1.7.3 Induction Potential for Drug-Metabolizing Enzymes; 1.8 Experimental Approaches for In Vitro Evaluation of Drug-Drug Interaction Potential; 1.8.1 Study 1: Metabolic Phenotyping 1-Metabolite Identification; 1.8.2 Study 2: Metabolic Phenotyping 2-Identification of Major Metabolic Pathways 1.8.3 Study 3: Metabolic Phenotyping 3-Identification of P450 Isoform Pathways (P450 Phenotyping)1.8.4 Study 4: CYP Inhibitory Potential; 1.8.5 Study 5: Enzyme Induction Potential; 1.8.6 Study 6: In Vitro Empirical Drug-Drug Interactions; 1.9 Data Interpretation; 1.9.1 Pathway Evaluation; 1.9.2 P450 Inhibition; 1.9.3 P450 Induction; 1.10 Conclusion; References; 2 In Vitro Approaches to Anticipating Clinical Drug Interactions; 2.1 In Vitro Systems for Human CYP450 Metabolism; 2.1.1 Incubation Buffer (pH and Ionic Strength); 2.1.2 MgCl(2) and Cytochrome b(5); 2.1.3 Nonspecific Binding 2.1.4 Organic Solvents and Excipients2.2 Analysis of Data from In Vitro Systems; 2.2.1 Linear Transformation of Michaelis-Menten Equation (Lineweaver-Burk and Eadie-Hofstee); 2.2.2 Nonlinear Regression Analysis of Hyperbolic Kinetic Data; 2.2.3 Consideration of Non-Michaelis-Menten Kinetics; 2.3 Use of In Vitro Kinetic Data to Predict In Vivo Clearance; 2.3.1 Calculation of In Vitro (Predicted) Hepatic Clearance; 2.3.2 Comparison of In Vitro (Predicted) with In Vivo Hepatic Clearance; 2.4 Use of In Vitro Kinetic Data to Predict Drug-Drug Interactions 2.4.1 Choice of Probe Substrates for Inhibition Studies2.4.2 Determining the Mechanism of CYP450 Inhibition; 2.4.3 Prediction of In Vivo Drug-Drug Inhibition Interactions from In Vitro Data; 2.5 Consideration of Non-CYP Enzymatic Systems; 2.5.1 Flavin-Containing Monooxygenase (FMO); 2.5.2 UDP-glucuronosyltransferase (UGT); 2.5.3 Sulfotransferase (SULT); 2.5.4 N-Acetyltransferase (NAT); 2.5.5 Methyltransferase; 2.5.6 Epoxidase Hydrolase; 2.5.7 Aldehyde Oxidase and Dehydrogenase; 2.5.8 Glutathione-S-transferase (GST); 2.6 Summary; 2.7 Acknowledgments; References 3 Inhibition of Drug-Metabolizing Enzymes and Drug-Drug Interactions in Drug Discovery and Development |
| Record Nr. | UNINA-9910143982103321 |
| Hoboken, N.J., : Wiley-interscience, c2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug-drug interactions in pharmaceutical development / / edited by Albert P. Li
| Drug-drug interactions in pharmaceutical development / / edited by Albert P. Li |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley-interscience, c2008 |
| Descrizione fisica | 1 online resource (261 p.) |
| Disciplina |
615.7045
615/.7045 |
| Altri autori (Persone) | LiA. P |
| Collana | Wiley series in drug discovery and development |
| Soggetto topico |
Drug interactions
Drug development |
| ISBN |
1-282-02206-7
9786612022067 0-470-18792-1 0-470-18791-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
DRUG-DRUG INTERACTIONS IN PHARMACEUTICAL DEVELOPMENT; CONTENTS; Preface; Contributors; 1 In Vitro Evaluation of Metabolic Drug-Drug Interactions: Concepts and Practice; 1.1 Introduction; 1.2 Mechanisms of Adverse Drug-Drug Interactions; 1.2.1 Pharmacological Interactions; 1.2.2 Pharmacokinetic Interactions; 1.3 Drug Metabolism; 1.3.1 Phase I Oxidation; 1.3.2 Phase II Conjugation; 1.4 CYP Isoforms; 1.5 Human In Vitro Experimental Systems for Drug Metabolism; 1.5.1 Hepatocytes; 1.5.2 Liver Postmitochondrial Supernatant (PMS); 1.5.3 Human Liver Microsomes; 1.5.4 Recombinant P450 Isoforms (rCYP)
1.5.5 Cytosol1.6 Mechanisms of Metabolic Drug-Drug Interactions; 1.7 Mechanism-Based Approach for Evaluation of Drug-Drug Interaction Potential; 1.7.1 Metabolic Phenotyping; 1.7.2 Evaluation of Inhibitory Potential for Drug-Metabolizing Enzymes; 1.7.3 Induction Potential for Drug-Metabolizing Enzymes; 1.8 Experimental Approaches for In Vitro Evaluation of Drug-Drug Interaction Potential; 1.8.1 Study 1: Metabolic Phenotyping 1-Metabolite Identification; 1.8.2 Study 2: Metabolic Phenotyping 2-Identification of Major Metabolic Pathways 1.8.3 Study 3: Metabolic Phenotyping 3-Identification of P450 Isoform Pathways (P450 Phenotyping)1.8.4 Study 4: CYP Inhibitory Potential; 1.8.5 Study 5: Enzyme Induction Potential; 1.8.6 Study 6: In Vitro Empirical Drug-Drug Interactions; 1.9 Data Interpretation; 1.9.1 Pathway Evaluation; 1.9.2 P450 Inhibition; 1.9.3 P450 Induction; 1.10 Conclusion; References; 2 In Vitro Approaches to Anticipating Clinical Drug Interactions; 2.1 In Vitro Systems for Human CYP450 Metabolism; 2.1.1 Incubation Buffer (pH and Ionic Strength); 2.1.2 MgCl(2) and Cytochrome b(5); 2.1.3 Nonspecific Binding 2.1.4 Organic Solvents and Excipients2.2 Analysis of Data from In Vitro Systems; 2.2.1 Linear Transformation of Michaelis-Menten Equation (Lineweaver-Burk and Eadie-Hofstee); 2.2.2 Nonlinear Regression Analysis of Hyperbolic Kinetic Data; 2.2.3 Consideration of Non-Michaelis-Menten Kinetics; 2.3 Use of In Vitro Kinetic Data to Predict In Vivo Clearance; 2.3.1 Calculation of In Vitro (Predicted) Hepatic Clearance; 2.3.2 Comparison of In Vitro (Predicted) with In Vivo Hepatic Clearance; 2.4 Use of In Vitro Kinetic Data to Predict Drug-Drug Interactions 2.4.1 Choice of Probe Substrates for Inhibition Studies2.4.2 Determining the Mechanism of CYP450 Inhibition; 2.4.3 Prediction of In Vivo Drug-Drug Inhibition Interactions from In Vitro Data; 2.5 Consideration of Non-CYP Enzymatic Systems; 2.5.1 Flavin-Containing Monooxygenase (FMO); 2.5.2 UDP-glucuronosyltransferase (UGT); 2.5.3 Sulfotransferase (SULT); 2.5.4 N-Acetyltransferase (NAT); 2.5.5 Methyltransferase; 2.5.6 Epoxidase Hydrolase; 2.5.7 Aldehyde Oxidase and Dehydrogenase; 2.5.8 Glutathione-S-transferase (GST); 2.6 Summary; 2.7 Acknowledgments; References 3 Inhibition of Drug-Metabolizing Enzymes and Drug-Drug Interactions in Drug Discovery and Development |
| Record Nr. | UNINA-9910818381003321 |
| Hoboken, N.J., : Wiley-interscience, c2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Handbook of food-drug interactions / / edited by Beverly J. McCabe, Eric H. Frankel, Jonathan J. Wolfe
| Handbook of food-drug interactions / / edited by Beverly J. McCabe, Eric H. Frankel, Jonathan J. Wolfe |
| Pubbl/distr/stampa | Boca Raton, Fla. : , : CRC Press, , 2003 |
| Descrizione fisica | 1 online resource (582 p.) |
| Disciplina | 615/.7045 |
| Altri autori (Persone) |
FrankelEric H
McCabeBeverly J WolfeJonathan James <1944-> |
| Collana | Nutrition Assessment |
| Soggetto topico | Drug-nutrient interactions |
| Soggetto genere / forma | Electronic books. |
| ISBN |
0-429-20832-4
1-135-50458-X 1-280-24061-X 9786610240616 0-203-49024-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Book Cover; Title; Copyright; Preface; The Editors; Contributors; Contents; CHAPTER 1 Pharmacy: Basic Concepts; CHAPTER 2 Biopharmaceutics of Orally Ingested Products; CHAPTER 3 Drug Interactions: Basic Concepts; CHAPTER 4 Nutrition and Metabolism; CHAPTER 5 Food and Nutrition Update; CHAPTER 6 Monitoring Nutritional Status in Drug Regimens; CHAPTER 7 Gastrointestinal and Metabolic Disorders and Drugs; CHAPTER 8 Drug Interactions in Nutrition Support; CHAPTER 9 Alcohol and Nutrition; CHAPTER 10 Nutrition and Drug Regimens in Older Persons; CHAPTER 11 Obesity and Appetite Drugs
CHAPTER 12 Nonprescription Drug and Nutrient InteractionsCHAPTER 13 Herbal and Dietary Supplement Interactions with Drugs; CHAPTER 14 Dietary Counseling to Prevent Food-Drug Interactions; CHAPTER 15 Prevention of Food-Drug Interactions; CHAPTER 16 Drug-Nutrient Interactions and JCAHO Standards; CHAPTER 17 Computers in Nutrient-Drug Interaction Management: Understanding the Past and the Present, Building a Framework...; APPENDIX A.1 Drug Side Effects; APPENDIX A.2 Brand Name Medications and Side Effects; APPENDIX A.3 Generic Name Medications and Side Effects APPENDIX A.4 Most Commonly Prescribed Trade Name DrugsAPPENDIX A.5 Most Commonly Prescribed Generic Drugs; APPENDIX A.6 pH of Bodily Fluids; APPENDIX A.7 Weight-Mass Conversions; APPENDIX A.8 Approximate Volume Conversions; APPENDIX A.9 Electrolyte Content of Common IV Solutions; APPENDIX B.1 Milliequivalent/Milligram Conversions for Commonly Used Salts; APPENDIX B.2 Average pH Values of Some Common Beverages and Foods; APPENDIX B.3 Commonly Used Electrolyte Additives for Intravenous Therapy; APPENDIX B.4 Commonly Used Micronutrient Additives for Intravenous Therapy APPENDIX C.1 Food Storage Guidelines for the General Population and for High-Risk PopulationsAPPENDIX C.2 Guidelines for Drug Approval (U.S. Food and Drug Administration); APPENDIX C.3 Grapefruit Juice-Drug Interactions and Their Clinical Significance; APPENDIX C.4 Guide to Gliadin in Drugs; APPENDIX C.5 Foods Containing Gliadin; APPENDIX C.6 Food Carbohydrate Replacements for Illness or Hypoglycemia; APPENDIX D.1 Tyramine Content of Foods and Beverages in ug/g or ug/mL; APPENDIX D.2 Histamine Content of Foods and Beverages in ug/g or ug/mL; APPENDIX D.3 Calcium Content of Selected Foods APPENDIX D.4 Vitamin K1 (Phylloquinone) Content of Foods in ug/100 g and ug/serving (in g or mL)APPENDIX D.5 Iron Content in Selected Foods; APPENDIX D.6 Magnesium Content in Selected Foods; APPENDIX D.7 Phosphorus Content in Selected Foods; APPENDIX D.8 Potassium Content in Selected Foods; APPENDIX D.9 Sodium Content in Selected Foods; APPENDIX D.10 Zinc Content in Selected Foods; APPENDIX D.11 Oxalate Content by High, Moderate, and Little or No Oxalate Categories; APPENDIX D.12 Dietary Caffeine and Other Methylxanthines; APPENDIX D.13 Caffeine Content of Common Beverages and Foods APPENDIX D.14 Theobromine in Foods |
| Record Nr. | UNINA-9910450110903321 |
| Boca Raton, Fla. : , : CRC Press, , 2003 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Handbook of food-drug interactions / / edited by Beverly J. McCabe, Eric H. Frankel, Jonathan J. Wolfe
| Handbook of food-drug interactions / / edited by Beverly J. McCabe, Eric H. Frankel, Jonathan J. Wolfe |
| Pubbl/distr/stampa | Boca Raton, Fla. : , : CRC Press, , 2003 |
| Descrizione fisica | 1 online resource (582 p.) |
| Disciplina | 615/.7045 |
| Altri autori (Persone) |
FrankelEric H
McCabeBeverly J WolfeJonathan James <1944-> |
| Collana | Nutrition Assessment |
| Soggetto topico | Drug-nutrient interactions |
| ISBN |
1-135-50457-1
0-429-20832-4 1-135-50458-X 1-280-24061-X 9786610240616 0-203-49024-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Book Cover; Title; Copyright; Preface; The Editors; Contributors; Contents; CHAPTER 1 Pharmacy: Basic Concepts; CHAPTER 2 Biopharmaceutics of Orally Ingested Products; CHAPTER 3 Drug Interactions: Basic Concepts; CHAPTER 4 Nutrition and Metabolism; CHAPTER 5 Food and Nutrition Update; CHAPTER 6 Monitoring Nutritional Status in Drug Regimens; CHAPTER 7 Gastrointestinal and Metabolic Disorders and Drugs; CHAPTER 8 Drug Interactions in Nutrition Support; CHAPTER 9 Alcohol and Nutrition; CHAPTER 10 Nutrition and Drug Regimens in Older Persons; CHAPTER 11 Obesity and Appetite Drugs
CHAPTER 12 Nonprescription Drug and Nutrient InteractionsCHAPTER 13 Herbal and Dietary Supplement Interactions with Drugs; CHAPTER 14 Dietary Counseling to Prevent Food-Drug Interactions; CHAPTER 15 Prevention of Food-Drug Interactions; CHAPTER 16 Drug-Nutrient Interactions and JCAHO Standards; CHAPTER 17 Computers in Nutrient-Drug Interaction Management: Understanding the Past and the Present, Building a Framework...; APPENDIX A.1 Drug Side Effects; APPENDIX A.2 Brand Name Medications and Side Effects; APPENDIX A.3 Generic Name Medications and Side Effects APPENDIX A.4 Most Commonly Prescribed Trade Name DrugsAPPENDIX A.5 Most Commonly Prescribed Generic Drugs; APPENDIX A.6 pH of Bodily Fluids; APPENDIX A.7 Weight-Mass Conversions; APPENDIX A.8 Approximate Volume Conversions; APPENDIX A.9 Electrolyte Content of Common IV Solutions; APPENDIX B.1 Milliequivalent/Milligram Conversions for Commonly Used Salts; APPENDIX B.2 Average pH Values of Some Common Beverages and Foods; APPENDIX B.3 Commonly Used Electrolyte Additives for Intravenous Therapy; APPENDIX B.4 Commonly Used Micronutrient Additives for Intravenous Therapy APPENDIX C.1 Food Storage Guidelines for the General Population and for High-Risk PopulationsAPPENDIX C.2 Guidelines for Drug Approval (U.S. Food and Drug Administration); APPENDIX C.3 Grapefruit Juice-Drug Interactions and Their Clinical Significance; APPENDIX C.4 Guide to Gliadin in Drugs; APPENDIX C.5 Foods Containing Gliadin; APPENDIX C.6 Food Carbohydrate Replacements for Illness or Hypoglycemia; APPENDIX D.1 Tyramine Content of Foods and Beverages in ug/g or ug/mL; APPENDIX D.2 Histamine Content of Foods and Beverages in ug/g or ug/mL; APPENDIX D.3 Calcium Content of Selected Foods APPENDIX D.4 Vitamin K1 (Phylloquinone) Content of Foods in ug/100 g and ug/serving (in g or mL)APPENDIX D.5 Iron Content in Selected Foods; APPENDIX D.6 Magnesium Content in Selected Foods; APPENDIX D.7 Phosphorus Content in Selected Foods; APPENDIX D.8 Potassium Content in Selected Foods; APPENDIX D.9 Sodium Content in Selected Foods; APPENDIX D.10 Zinc Content in Selected Foods; APPENDIX D.11 Oxalate Content by High, Moderate, and Little or No Oxalate Categories; APPENDIX D.12 Dietary Caffeine and Other Methylxanthines; APPENDIX D.13 Caffeine Content of Common Beverages and Foods APPENDIX D.14 Theobromine in Foods |
| Record Nr. | UNINA-9910783400703321 |
| Boca Raton, Fla. : , : CRC Press, , 2003 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Handbook of food-drug interactions / / edited by Beverly J. McCabe, Eric H. Frankel, Jonathan J. Wolfe
| Handbook of food-drug interactions / / edited by Beverly J. McCabe, Eric H. Frankel, Jonathan J. Wolfe |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Boca Raton, Fla., : CRC Press, c2003 |
| Descrizione fisica | 1 online resource (582 p.) |
| Disciplina | 615/.7045 |
| Altri autori (Persone) |
McCabeBeverly J
WolfeJonathan James <1944-> FrankelEric H |
| Collana | Nutrition Assessment |
| Soggetto topico | Drug-nutrient interactions |
| ISBN |
1-135-50457-1
0-429-20832-4 1-135-50458-X 1-280-24061-X 9786610240616 0-203-49024-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Book Cover; Title; Copyright; Preface; The Editors; Contributors; Contents; CHAPTER 1 Pharmacy: Basic Concepts; CHAPTER 2 Biopharmaceutics of Orally Ingested Products; CHAPTER 3 Drug Interactions: Basic Concepts; CHAPTER 4 Nutrition and Metabolism; CHAPTER 5 Food and Nutrition Update; CHAPTER 6 Monitoring Nutritional Status in Drug Regimens; CHAPTER 7 Gastrointestinal and Metabolic Disorders and Drugs; CHAPTER 8 Drug Interactions in Nutrition Support; CHAPTER 9 Alcohol and Nutrition; CHAPTER 10 Nutrition and Drug Regimens in Older Persons; CHAPTER 11 Obesity and Appetite Drugs
CHAPTER 12 Nonprescription Drug and Nutrient InteractionsCHAPTER 13 Herbal and Dietary Supplement Interactions with Drugs; CHAPTER 14 Dietary Counseling to Prevent Food-Drug Interactions; CHAPTER 15 Prevention of Food-Drug Interactions; CHAPTER 16 Drug-Nutrient Interactions and JCAHO Standards; CHAPTER 17 Computers in Nutrient-Drug Interaction Management: Understanding the Past and the Present, Building a Framework...; APPENDIX A.1 Drug Side Effects; APPENDIX A.2 Brand Name Medications and Side Effects; APPENDIX A.3 Generic Name Medications and Side Effects APPENDIX A.4 Most Commonly Prescribed Trade Name DrugsAPPENDIX A.5 Most Commonly Prescribed Generic Drugs; APPENDIX A.6 pH of Bodily Fluids; APPENDIX A.7 Weight-Mass Conversions; APPENDIX A.8 Approximate Volume Conversions; APPENDIX A.9 Electrolyte Content of Common IV Solutions; APPENDIX B.1 Milliequivalent/Milligram Conversions for Commonly Used Salts; APPENDIX B.2 Average pH Values of Some Common Beverages and Foods; APPENDIX B.3 Commonly Used Electrolyte Additives for Intravenous Therapy; APPENDIX B.4 Commonly Used Micronutrient Additives for Intravenous Therapy APPENDIX C.1 Food Storage Guidelines for the General Population and for High-Risk PopulationsAPPENDIX C.2 Guidelines for Drug Approval (U.S. Food and Drug Administration); APPENDIX C.3 Grapefruit Juice-Drug Interactions and Their Clinical Significance; APPENDIX C.4 Guide to Gliadin in Drugs; APPENDIX C.5 Foods Containing Gliadin; APPENDIX C.6 Food Carbohydrate Replacements for Illness or Hypoglycemia; APPENDIX D.1 Tyramine Content of Foods and Beverages in ug/g or ug/mL; APPENDIX D.2 Histamine Content of Foods and Beverages in ug/g or ug/mL; APPENDIX D.3 Calcium Content of Selected Foods APPENDIX D.4 Vitamin K1 (Phylloquinone) Content of Foods in ug/100 g and ug/serving (in g or mL)APPENDIX D.5 Iron Content in Selected Foods; APPENDIX D.6 Magnesium Content in Selected Foods; APPENDIX D.7 Phosphorus Content in Selected Foods; APPENDIX D.8 Potassium Content in Selected Foods; APPENDIX D.9 Sodium Content in Selected Foods; APPENDIX D.10 Zinc Content in Selected Foods; APPENDIX D.11 Oxalate Content by High, Moderate, and Little or No Oxalate Categories; APPENDIX D.12 Dietary Caffeine and Other Methylxanthines; APPENDIX D.13 Caffeine Content of Common Beverages and Foods APPENDIX D.14 Theobromine in Foods |
| Record Nr. | UNINA-9910813375503321 |
| Boca Raton, Fla., : CRC Press, c2003 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||